Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
Arch Neurol 2003; 60(12):1696-702AN

Abstract

BACKGROUND

Tau and beta-amyloid (Abeta) are proposed diagnostic biomarkers for Alzheimer disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other dementias. To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed dementia groups and cognitively normal subjects.

OBJECTIVES

To correlate antemortem cerebrospinal fluid (CSF) tau and Abeta levels with definitive dementia diagnosis in a diverse group of patients; to calculate statistics for CSF tau and Abeta.

DESIGN

Prospective study.

SETTING

Ten clinics experienced in the diagnosis of neurodegenerative dementias. Patients One hundred six patients with dementia and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects.

MAIN OUTCOME MEASURES

Correlation of CSF tau and Abeta with final diagnosis.

RESULTS

Mean tau level was 612 pg/mL for the 74 patients with AD, 272 pg/mL for 10 patients with frontal dementia, 282 pg/mL for 3 patients with dementia with Lewy bodies, and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 patients with AD. Abeta42 was reduced in patients with AD (61 fmol/mL) compared with patients with frontal dementia (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with patients with dementia with Lewy bodies (14 fmol/mL) or prion disease (60 fmol/mL).

CONCLUSIONS

Elevated CSF tau levels are associated with AD pathology and can help discriminate AD from other dementing disorders. However, some patients with AD have a level less than the mean +/- 2 SDs of the cognitively normal cohort.

Authors+Show Affiliations

Departments of Neurology, Center for Neuerodegenerative Disease Research, alzheimer's Disease Center, Philadelphia, PA 19104, USA. clarkc@mail.med.upenn.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14676043

Citation

Clark, Christopher M., et al. "Cerebrospinal Fluid Tau and Beta-amyloid: How Well Do These Biomarkers Reflect Autopsy-confirmed Dementia Diagnoses?" Archives of Neurology, vol. 60, no. 12, 2003, pp. 1696-702.
Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60(12):1696-702.
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., ... Trojanowski, J. Q. (2003). Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of Neurology, 60(12), pp. 1696-702.
Clark CM, et al. Cerebrospinal Fluid Tau and Beta-amyloid: How Well Do These Biomarkers Reflect Autopsy-confirmed Dementia Diagnoses. Arch Neurol. 2003;60(12):1696-702. PubMed PMID: 14676043.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? AU - Clark,Christopher M, AU - Xie,Sharon, AU - Chittams,Jesse, AU - Ewbank,Douglas, AU - Peskind,Elaine, AU - Galasko,Douglas, AU - Morris,John C, AU - McKeel,Daniel W,Jr AU - Farlow,Martin, AU - Weitlauf,Sharon L, AU - Quinn,Joseph, AU - Kaye,Jeffrey, AU - Knopman,David, AU - Arai,Hiroyuki, AU - Doody,Rachelle S, AU - DeCarli,Charles, AU - Leight,Susan, AU - Lee,Virginia M-Y, AU - Trojanowski,John Q, PY - 2003/12/17/pubmed PY - 2004/1/8/medline PY - 2003/12/17/entrez SP - 1696 EP - 702 JF - Archives of neurology JO - Arch. Neurol. VL - 60 IS - 12 N2 - BACKGROUND: Tau and beta-amyloid (Abeta) are proposed diagnostic biomarkers for Alzheimer disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other dementias. To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed dementia groups and cognitively normal subjects. OBJECTIVES: To correlate antemortem cerebrospinal fluid (CSF) tau and Abeta levels with definitive dementia diagnosis in a diverse group of patients; to calculate statistics for CSF tau and Abeta. DESIGN: Prospective study. SETTING: Ten clinics experienced in the diagnosis of neurodegenerative dementias. Patients One hundred six patients with dementia and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects. MAIN OUTCOME MEASURES: Correlation of CSF tau and Abeta with final diagnosis. RESULTS: Mean tau level was 612 pg/mL for the 74 patients with AD, 272 pg/mL for 10 patients with frontal dementia, 282 pg/mL for 3 patients with dementia with Lewy bodies, and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 patients with AD. Abeta42 was reduced in patients with AD (61 fmol/mL) compared with patients with frontal dementia (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with patients with dementia with Lewy bodies (14 fmol/mL) or prion disease (60 fmol/mL). CONCLUSIONS: Elevated CSF tau levels are associated with AD pathology and can help discriminate AD from other dementing disorders. However, some patients with AD have a level less than the mean +/- 2 SDs of the cognitively normal cohort. SN - 0003-9942 UR - https://www.unboundmedicine.com/medline/citation/14676043/Cerebrospinal_fluid_tau_and_beta_amyloid:_how_well_do_these_biomarkers_reflect_autopsy_confirmed_dementia_diagnoses L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/vol/60/pg/1696 DB - PRIME DP - Unbound Medicine ER -